-uridine
Uridine-like nucleosides for viral infections or cancer.
- Drugs ending in -uridine: 22
- Approved somewhere: 8
- With a US drug page: 7
- Stem
- -uridine
- Class
- Uridine-like nucleosides for viral infections or cancer
- Sub-stems
- -vudine
- Most common targets
- DNA (4), POL (4), P (3), TYMS (2), CDA (1), RNA (1), REVERSE, TRANSCRIPTASE (1), DNA polymerase catalytic subunit (1)
Approved and clinical-stage drugs in ChEMBL whose names ending in -uridine or one of its sub-stems, matched by spelling; those with a US drug page link to it.
| Acts on | |||
|---|---|---|---|
| Floxuridine | Approved | TYMS | Thymidylate synthase inhibitor |
| Idoxuridine | Approved | DNA | DNA inhibitor |
| Trifluridine | Approved | DNA | DNA inhibitor |
| Cedazuridine | Approved | CDA | Cytidine deaminase inhibitor |
| Doxifluridine | Phase 3 | DNA, RNA, TYMS | DNA disrupting agent |
| Broxuridine | Phase 2 | — | — |
| Fialuridine | Phase 2 | — | — |
| Ropidoxuridine | Phase 2 | — | — |
| Tetrahydrouridine | Phase 2 | — | — |
| Fosifloxuridine nafalbenamide | Phase 1 | — | — |
| Raluridine | Phase 1 | — | — |
| Lamivudine | Approved | POL, DNA, P | Human immunodeficiency virus type 1 reverse transcriptase inhibitor |
| Stavudine | Approved | POL | Human immunodeficiency virus type 1 reverse transcriptase inhibitor |
| Telbivudine | Approved | P | DNA polymerase/reverse transcriptase inhibitor |
| Zidovudine | Approved | POL | Human immunodeficiency virus type 1 reverse transcriptase inhibitor |
| Clevudine | Phase 3 | P | Protein P inhibitor |
| Alovudine | Phase 2 | — | — |
| Brivudine | Phase 2 | — | — |
| Censavudine | Phase 2 | POL, REVERSE, TRANSCRIPTASE | Human immunodeficiency virus type 1 reverse transcriptase inhibitor |
| Fosclevudine alafenamide | Phase 2 | — | — |
| Sorivudine | Phase 2 | DNA polymerase catalytic subunit | DNA polymerase catalytic subunit inhibitor |
| Valnivudine | Phase 2 | — | — |
Stem from WHO, The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances (2024); description written by Arca. Drugs, stages, targets and mechanisms from ChEMBL (CC BY-SA 3.0). WHO